CAMBRIDGE INNOVATION CAPITAL
EXVASTAT IMPACT CASE STUDIES
SAVING LIVES BY IMPROVING THE TREATMENT OF ARDS FROM ANY CAUSE
IMP RATING: B – BENEFIT STAKEHOLDERS Exvastat is developing a pioneering new treatment for Acute Respiratory Distress Syndrome. We are immensely grateful to CIC for their belief in the underlying science, their support in building the corporate infrastructure to allow the company to grow, their input to the development programme and for their continued financial support to the company through its journey. DAVID CAVALLA CEO
We have applied the Impact Management Project (IMP) framework (see IBC for further details) in summarising the impact of a selection of our investments.
22
IMPACT AND ESG REPORT FOR THE YEAR ENDED 31 MARCH 2021
